Cassava Sciences Stock Price Up 46% for the Week On New Test/Treatment Data for Alzheimer’s Disease

Cassava sciences stock price is down 6.91% as traders look to bank profits made on the stock this week.

The company announced new data for testing and treatment of Alzheimer’s disease, sending its stocks soaring by 29.5% in midweek trading. Cassava Sciences is developing a revolutionary blood test (SavaDx) for detecting Alzheimer’s disease and Simufilam, a new treatment for the debilitating illness. Data will be presented on 26 July and 29 July. 

Despite today’s correction, Cassava Sciences is up 46.24% as of writing.

Cassava Sciences Stock Price Outlook

Price is now testing the 4 February high at 117.12. A breakdown of this area brings the 112.88 support (50% Fibonacci extension and 9 July high) into the picture. Any further declines in price have to take out 103.34 and 95.75, targeting the 90.00 psychological support and 3 February high.

A bounce on the present support or any of the subsequent support levels below ultimately needs to take out the present all-time high at 130.47 to aim for potential new highs at 136.00 (78.6% Fibonacci extension) and 144.09 (88.6% Fibonacci extension).

Don’t miss a beat! Follow us on Telegram and Twitter.

Cassava Sciences: Daily Chart

Follow Eno on Twitter.